XML 249 R192.htm IDEA: XBRL DOCUMENT
v3.25.0.1

Off balance sheet commitments - Additional Information (Details) € in Millions, $ in Millions |  |  |  |  | 3 Months Ended | 9 Months Ended | 12 Months Ended |  |  |  |  |  |  |
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Sep. 12, 2024 EUR (€) | May 10, 2024 USD ($) | Mar. 15, 2022 EUR (€) | Feb. 27, 2017 EUR (€) | Mar. 31, 2022 | Dec. 31, 2022 EUR (€) | Dec. 31, 2024 EUR (€) | Dec. 31, 2022 EUR (€) | Dec. 31, 2023 EUR (€) | Apr. 27, 2023 EUR (€) | Nov. 08, 2022 target | Aug. 17, 2022 target | Mar. 29, 2022 target | Jan. 07, 2022 molecule | Feb. 28, 2014
Provisions And Other Current And Non-Current Liabilities [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Commitments related to research and development relating to projects in research phase |  |  |  |  |  |  | € 14,400 |  | € 16,800 |  |  |  |  |  |
Commitments related to research and development payments contingent upon attainment of sales targets |  |  |  |  |  |  | 15,200 |  | 17,900 |  |  |  |  |  |
Commitments related to collaboration, discovery, development and commercialization agreements |  |  |  |  |  |  | 13,000 |  | 10,000 |  |  |  |  |  |
Commitments related to attainment of regulatory and sales milestones for commercialized products |  |  |  |  |  |  | 11,200 |  | 8,500 |  |  |  |  |  |
Cumulative development costs incurred |  |  |  |  |  |  | 9,700 |  |  |  |  |  |  |  |
Total credit facilities |  |  |  |  |  | € 8,000 | 8,000 | € 8,000 | 8,000 |  |  |  |  |  |
Commitments received in respect of disposals proceeds receivable and contingent consideration on divestments |  |  |  |  |  |  | € 500 |  |  |  |  |  |  |  |
World Health Organization |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Provisions And Other Current And Non-Current Liabilities [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of pandemic vaccines agreed to transfer |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 7.50%
Percentage of pandemic vaccines agreed to reserve |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 7.50%
Joint ventures |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Provisions And Other Current And Non-Current Liabilities [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of future development expense funded by other party |  |  |  | 5000.00% |  |  |  |  |  |  |  |  |  |  |
Provention Bio, Inc | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Provisions And Other Current And Non-Current Liabilities [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Commitments related to milestone payments for projects under collaboration agreements |  |  |  |  |  |  |  |  |  | € 946 |  |  |  |  |
IGM Biosciences, Inc | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Provisions And Other Current And Non-Current Liabilities [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of oncology targets under collaboration agreement | target |  |  |  |  |  |  |  |  |  |  |  |  | 3 |  |
Number of immunology or inflammation targets under collaboration agreement | target |  |  |  |  |  |  |  |  |  |  |  |  | 3 |  |
Atomwise | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Provisions And Other Current And Non-Current Liabilities [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of drug targets under collaboration agreement | target |  |  |  |  |  |  |  |  |  |  |  | 5 |  |  |
Insilico Medicine | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Provisions And Other Current And Non-Current Liabilities [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of therapeutic targets under collaboration agreement | target |  |  |  |  |  |  |  |  |  |  | 6 |  |  |  |
Lonza | Joint ventures |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Provisions And Other Current And Non-Current Liabilities [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Investments in joint ventures |  |  |  | € 300 |  |  |  |  |  |  |  |  |  |  |
Percentage of future development expense funded by company |  |  |  | 50.00% |  |  |  |  |  |  |  |  |  |  |
Amounts payable partners in collaboration agreements |  |  |  | € 600 |  |  |  |  |  |  |  |  |  |  |
Novavax |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Provisions And Other Current And Non-Current Liabilities [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Commitments related to research and development relating to projects in research phase | $ |  | $ 700,000 |  |  |  |  |  |  |  |  |  |  |  |  |
Commitments related to attainment of regulatory and sales milestones for commercialized products | $ |  | 1,200 |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront payment | $ |  | 500,000 |  |  |  |  |  |  |  |  |  |  |  |  |
Commitments Related To Attainment Of Additional Regulatory And Sales Milestones For Commercialized Products | $ |  | $ 200,000 |  |  |  |  |  |  |  |  |  |  |  |  |
Financial interest in principal fully consolidated companies |  | 500.00% |  |  |  |  |  |  |  |  |  |  |  |  |
RadioMedix, Inc. and Orano Med |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Provisions And Other Current And Non-Current Liabilities [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Commitments related to attainment of regulatory and sales milestones for commercialized products | € 220 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront payment | € 100 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Exscentia | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Provisions And Other Current And Non-Current Liabilities [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of novel small molecule candidates developed | molecule |  |  |  |  |  |  |  |  |  |  |  |  |  | 15 |
Corxel Pharmaceuticals |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Provisions And Other Current And Non-Current Liabilities [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Commitments Related To Attainment Of Additional Regulatory And Sales Milestones For Commercialized Products | $ |  | $ 150 |  |  |  |  |  |  |  |  |  |  |  |  |
Antibodies Collaboration agreement | Blackstone Life Sciences |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Provisions And Other Current And Non-Current Liabilities [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Commitments related to maximum payments for projects under collaboration agreement |  |  | € 300 |  |  |  |  |  |  |  |  |  |  |  |
Antibodies Collaboration agreement | Regeneron Pharmaceuticals, INC |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Provisions And Other Current And Non-Current Liabilities [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Maximum additional profit-share, in percentage of Regeneron's quarterly profit (in percent) |  |  |  |  | 10.00% | 20.00% |  |  |  |  |  |  |  |  |
Percentage of cumulative development costs reimbursed |  |  |  |  |  |  | 50.00% | 50.00% |  |  |  |  |  |  |
Commitments received for development costs |  |  |  |  |  |  | € 1,600 |  | 2,100 |  |  |  |  |  |
Ablynx NV |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Provisions And Other Current And Non-Current Liabilities [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Commitments related to collaboration, discovery, development and commercialization agreements |  |  |  |  |  |  | 700 |  | 900 |  |  |  |  |  |
Kymab |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Provisions And Other Current And Non-Current Liabilities [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Commitments related to collaboration, discovery, development and commercialization agreements |  |  |  |  |  |  | 300 |  | 200 |  |  |  |  |  |
Provention Bio |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Provisions And Other Current And Non-Current Liabilities [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Commitments related to collaboration, discovery, development and commercialization agreements |  |  |  |  |  |  | € 400 |  | € 300 |  |  |  |  |  |

X
- Definition The amount of investments in joint ventures in an entity's separate financial statements. [Refer: Joint ventures [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 27 -IssueDate 2023-01-01 -Paragraph 10 -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2023-en-r&anchor=para_10&doctype=Standard -URIDate 2023-03-23 + Details
Name: | ifrs-full_InvestmentsInJointVentures
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The proportion of ownership interest in a subsidiary attributable to the entity. [Refer: Subsidiaries [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 27 -IssueDate 2023-01-01 -Paragraph 17 -Subparagraph b -Clause iii -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2023-en-r&anchor=para_17_b_iii&doctype=Standard -URIDate 2023-03-23 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 27 -IssueDate 2023-01-01 -Paragraph 16 -Subparagraph b -Clause iii -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2023-en-r&anchor=para_16_b_iii&doctype=Standard -URIDate 2023-03-23 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 12 -IssueDate 2023-01-01 -Paragraph 19B -Subparagraph c -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_19B_c&doctype=Standard -URIDate 2023-03-23 + Details
Name: | ifrs-full_ProportionOfOwnershipInterestInSubsidiary
Namespace Prefix: | ifrs-full_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of undrawn borrowing facilities that may be available for future operating activities and to settle capital commitments. [Refer: Capital commitments] + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Name IAS -Number 7 -IssueDate 2023-01-01 -Paragraph 50 -Subparagraph a -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_50_a&doctype=Standard -URIDate 2023-03-23 + Details
Name: | ifrs-full_UndrawnBorrowingFacilities
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amounts payable partners in collaboration agreements. + References No definition available. + Details
Name: | sny_AmountsPayablePartnersInCollaborationAgreements
Namespace Prefix: | sny_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Commitments Received For Development Costs + References No definition available. + Details
Name: | sny_CommitmentsReceivedForDevelopmentCosts
Namespace Prefix: | sny_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Commitments Related To Attainment Of Additional Regulatory And Sales Milestones For Commercialized Products + References No definition available. + Details
Name: | sny_CommitmentsRelatedToAttainmentOfAdditionalRegulatoryAndSalesMilestonesForCommercializedProducts
Namespace Prefix: | sny_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Commitments Related To Attainment Of Regulatory And Sales Milestones For Commercialized Products + References No definition available. + Details
Name: | sny_CommitmentsRelatedToAttainmentOfRegulatoryAndSalesMilestonesForCommercializedProducts
Namespace Prefix: | sny_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Commitments Related To Collaboration, Discovery, Development And Commercialization Agreements + References No definition available. + Details
Name: | sny_CommitmentsRelatedToCollaborationDiscoveryDevelopmentAndCommercializationAgreements
Namespace Prefix: | sny_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Commitments Related To Maximum Payments For Projects Under Collaboration Agreement + References No definition available. + Details
Name: | sny_CommitmentsRelatedToMaximumPaymentsForProjectsUnderCollaborationAgreement
Namespace Prefix: | sny_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Commitments Related To Milestone Payments For Projects Under Collaboration Agreement + References No definition available. + Details
Name: | sny_CommitmentsRelatedToMilestonePaymentsForProjectsUnderCollaborationAgreement
Namespace Prefix: | sny_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Commitments related to r and d payments contingent upon attainment of sales targets. + References No definition available. + Details
Name: | sny_CommitmentsRelatedToResearchAndDevelopmentPaymentsContingentUponAttainmentOfSalesTargets
Namespace Prefix: | sny_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Commitments Related To Research And Development Relating To Projects In Research Phase + References No definition available. + Details
Name: | sny_CommitmentsRelatedToResearchAndDevelopmentRelatingToProjectsInResearchPhase
Namespace Prefix: | sny_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Cumulative Development Costs Incurred + References No definition available. + Details
Name: | sny_CumulativeDevelopmentCostsIncurred
Namespace Prefix: | sny_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Number Of Drug Targets Under Collaboration Agreement + References No definition available. + Details
Name: | sny_NumberOfDrugTargetsUnderCollaborationAgreement
Namespace Prefix: | sny_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number Of Immunology Or Inflammation Targets Under Collaboration Agreement + References No definition available. + Details
Name: | sny_NumberOfImmunologyOrInflammationTargetsUnderCollaborationAgreement
Namespace Prefix: | sny_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number Of Novel Small Molecule Candidates To Be Developed Under Collaboration Agreement + References No definition available. + Details
Name: | sny_NumberOfNovelSmallMoleculeCandidatesToBeDevelopedUnderCollaborationAgreement
Namespace Prefix: | sny_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number Of Oncology Targets Under Collaboration Agreement + References No definition available. + Details
Name: | sny_NumberOfOncologyTargetsUnderCollaborationAgreement
Namespace Prefix: | sny_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number Of Therapeutic Targets Under Collaboration Agreement + References No definition available. + Details
Name: | sny_NumberOfTherapeuticTargetsUnderCollaborationAgreement
Namespace Prefix: | sny_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Off-Balance Sheet Commitments Received In Respect Of Disposals Proceeds Receivable And Contingent Consideration On Divestments + References No definition available. + Details
Name: | sny_OffBalanceSheetCommitmentsReceivedInRespectOfDisposalsProceedsReceivableAndContingentConsiderationOnDivestments
Namespace Prefix: | sny_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Percentage of cumulative development costs reimbursed. + References No definition available. + Details
Name: | sny_PercentageOfCumulativeDevelopmentCostsReimbursed
Namespace Prefix: | sny_
Data Type: | dtr-types1:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of future development expense funded by company. + References No definition available. + Details
Name: | sny_PercentageOfFutureDevelopmentExpenseFundedByCompany
Namespace Prefix: | sny_
Data Type: | dtr-types1:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of future development expense funded by other party. + References No definition available. + Details
Name: | sny_PercentageOfFutureDevelopmentExpenseFundedByOtherParty
Namespace Prefix: | sny_
Data Type: | dtr-types1:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of profit share on counter parties profit. + References No definition available. + Details
Name: | sny_PercentageOfProfitShareOnCounterpartiesProfit
Namespace Prefix: | sny_
Data Type: | dtr-types1:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Provisions and other current and non-current liabilities. + References No definition available. + Details
Name: | sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems
Namespace Prefix: | sny_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Reserve percentage of pandemic vaccines. + References No definition available. + Details
Name: | sny_ReservePercentageOfPandemicVaccines
Namespace Prefix: | sny_
Data Type: | dtr-types1:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Transfer percentage of pandemic vaccines. + References No definition available. + Details
Name: | sny_TransferPercentageOfPandemicVaccines
Namespace Prefix: | sny_
Data Type: | dtr-types1:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Upfront payments. + References No definition available. + Details
Name: | sny_UpfrontPayments
Namespace Prefix: | sny_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | ifrs-full_CategoriesOfRelatedPartiesAxis=sny_WorldHealthOrganizationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_JointVenturesAxis=ifrs-full_JointVenturesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_CounterpartiesAxis=sny_ProventionBioIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_CounterpartiesAxis=sny_IGMBiosciencesIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_CounterpartiesAxis=sny_AtomwiseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_CounterpartiesAxis=sny_InsilicoMedicineMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_CounterpartiesAxis=sny_LonzaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_CounterpartiesAxis=sny_NovavaxMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_CounterpartiesAxis=sny_RadioMedixInc.AndOranoMedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_CounterpartiesAxis=sny_ExscentiaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_CounterpartiesAxis=sny_CorxelPharmaceuticalsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | sny_PrincipalAlliancesAxis=sny_AntibodiesCollaborationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_CounterpartiesAxis=sny_BlackstoneLifeSciencesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_CounterpartiesAxis=sny_RegeneronPharmaceuticalsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_BusinessCombinationsAxis=sny_AblynxMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_BusinessCombinationsAxis=sny_KymabMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_BusinessCombinationsAxis=sny_ProventionBioMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |